Shermaine Tilley
Partner @ CTI Capital
Montréal, Canada
Shermaine Tilley is a Series B investor at CTI Capital in Montréal focused on Biotechnology and Medical. Dr. Tilley is a Partner at CTI Life Sciences Fund, L.P. Prior to joining CTI, Dr. Tilley was a Senior Vice President at Drug Royalty Corporation, a Bay Street private equity firm focused on biopharmaceutical investment. While at DRC she managed the due diligence and analysis group, and participated in transactions totaling over $200M. Before DRC,Dr. Tilley held faculty and research positions at the NYU School of Medicine and the Public Health Research Institute (PHRI), New York, and served on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health Small Business Innovation Research (SBIR) program.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Shermaine Tilley invests in
Stages Shermaine Tilley invests in
Countries Shermaine Tilley invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (56%)
- Medical 2 (22%)
- Health Care 2 (22%)
- Therapeutics 2 (22%)
- Health Diagnostics 2 (22%)
Stage
- Series B 2 (22%)
- Funding Round 2 (22%)
- Series A 1 (11%)
- Series C 1 (11%)
- Post-IPO Equity 1 (11%)
Country
- Canada 4 (44%)
- Spain 1 (11%)
- Singapore 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ability Pharmaceuticals
|
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The companydevelops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization. | $7.7M / Venture - Series Unknown / Mar 11, 2024 | |
IMV Inc
|
IMV Inc Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. IMV Inc has advanced two DepoVax-based cancer vaccinesinto Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. IMV Inc has key partnerships in the animal health sector including an agreement with Pfizer Animal Health. | $6.3M / Post-IPO Equity / Jun 08, 2016 | |
Xagenic
|
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $25.5M / Series B / Jul 14, 2014 | |
|
Xagenic
|
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $10M / Series A / Jan 30, 2012 | |
Zymeworks
|
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | $8.1M / Sep 22, 2011 | |
Enobia Pharma
|
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. | $50M / Series C / Aug 10, 2009 | |
|
Zymeworks
|
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | $3.2M / Jun 29, 2009 | |
|
Enobia Pharma
|
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. | $29.3M / Series B / Aug 01, 2007 | |
BeXcom
|
BeXcom, a privately held corporation founded in 1996, operates a global network of eCommerce hubs in the world's major trading zones. This global transaction infrastructure enables companies and exchanges to conduct business electronically locally or with multiple trading partners around the world.BeXcom's Commerce Service Providermodel provides and maintains all the required hardware and software to operate centralized B2B eCommerce solutions for their users. By building on the BeXcom infrastructure, supply chains, vertical markets and market makers can quickly implement or dramatically extend their eCommerce capabilities to cover the complete range of purchasing processes, from RFQ to settlement.BeXcom is the first company to integrate global financial, logistics, and certificate authority services into a global eCommerce infrastructure, ensuring all transactions are safe, secure, and verifiable.BeXcom helps their customers streamline business processes, reduce costs, expand markets and add value to their business by delivering the full potential of B2B eCommerce. | $75M / Mar 31, 2000 |
Co-Investors
About CTI Capital
CTI Capital is a venture capital fund that invests in development-stage, Canadian life sciences companies.
CTI Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Shermaine Tilley
Partner
|
|||
|
Bernard Casimir
Registered Representative
|
|||
|
François Soto
Research Analyst, Equity Market.
|
|||
|
Guylaine Couillard
Administrative Assistant
|
|||
Ivan Greenstein
Institutional Representative, Fixed Income
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shermaine Tilley invest in?
Shermaine Tilley invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shermaine Tilley?
Public channels for Shermaine Tilley include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shermaine Tilley last invest?
The most recent investment recorded for Shermaine Tilley closed in Mar 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
